Double-Punch combo tested to fight tough lymphoma when other treatments fail
NCT ID NCT06854159
Summary
This study is testing whether adding a new drug called odronextamab to standard CAR-T cell therapy works better for aggressive lymphoma. It will involve about 34 adults whose lymphoma has come back or hasn't responded to at least two prior treatments. The goal is to see if giving the drug both before and after the CAR-T therapy helps the body's immune system find and kill more cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.